TAS-102
Merck & Co., Inc. MRK · Colorectal Cancer; Colorectal Neoplasms
Key figures
Next catalyst
None scheduled
Only dates with a source are listed
Phase
Phase 3
Not recorded
Linked trials
3
From ClinicalTrials.gov
Latest FDA action
None on record
From Drugs@FDA
Recalls, shortages, patents and EU status at a glance
Key information
- Sponsor
- Merck & Co., Inc. MRK Source: Company record for Merck & Co., Inc. (opens in a new tab)
- Indications
- Colorectal Cancer; Colorectal Neoplasms Source: Conditions from ClinicalTrials.gov (opens in a new tab)
- Designations
- None recorded
- Next catalyst
- None scheduled
Development timeline
- Preclinical Completed
- Phase 1 Completed
- Phase 2 Completed
- Phase 3 Current stageFirst trial start 29 Mar 20213 linked trials
- Filed Not yet
- Approved Not yet
Overview
- Mechanism
- Not recorded
- Route
- Not recorded
- Modality
- Not recorded
- Specialties
- Not recorded
Overview text is written by HealthTrade editors.
Key dates
No catalysts yet. Editors add each date together with its source.
FDA designations
No FDA designations are on record for TAS-102. Editors add each one with its source.
Filed application
No filed application is on record for TAS-102. Approvals are listed under FDA actions.
FDA advisory committees
No FDA advisory committee meetings are on record for TAS-102.
Clinical trials
| Trial | Title | Phase | Status | Enrollment | Primary completion | Results posted |
|---|---|---|---|---|---|---|
| NCT05600309ClinicalTrials.gov record for NCT05600309 (opens in a new tab) | A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study | Phase 3 | Completed | 94 (actual) | 15 Aug 2024 (actual) | Yes First posted Results on ClinicalTrials.gov for NCT05600309 (opens in a new tab) |
Posted results on ClinicalTrials.gov for NCT05600309
Serious adverse events (Up to approximately 30 months): Favezelimab/Pembrolizumab 12 of 49; Standard of Care (Regorafenib or TAS-102) 13 of 44 Source: ClinicalTrials.gov results for NCT05600309 (opens in a new tab)· imported Posted results as ClinicalTrials.gov prints them: primary outcome analyses and serious adverse event totals only. Registry facts, not reviewed by HealthTrade and not investment advice; filing-derived results are listed separately. | ||||||
| NCT05064059ClinicalTrials.gov record for NCT05064059 (opens in a new tab) | A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) | Phase 3 | Completed | 441 (actual) | 15 Aug 2024 (actual) | Yes First posted Results on ClinicalTrials.gov for NCT05064059 (opens in a new tab) |
Posted results on ClinicalTrials.gov for NCT05064059
Serious adverse events (Up to approximately 38 months): Favezelimab/Pembrolizumab 75 of 221; Standard of Care (Regorafenib or TAS-102) 56 of 210 Source: ClinicalTrials.gov results for NCT05064059 (opens in a new tab)· imported Posted results as ClinicalTrials.gov prints them: primary outcome analyses and serious adverse event totals only. Registry facts, not reviewed by HealthTrade and not investment advice; filing-derived results are listed separately. Publications listing NCT05064059 (1), newest first
Citations from PubMed, U.S. National Library of Medicine; abstracts are not stored. A publication lists this study’s NCT number and may be a review that cites many studies. | ||||||
| NCT04776148ClinicalTrials.gov record for NCT04776148 (opens in a new tab) | Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) | Phase 3 | Completed | 563 (actual) | 27 Sep 2024 (actual) | Yes First posted Results on ClinicalTrials.gov for NCT04776148 (opens in a new tab) |
Posted results on ClinicalTrials.gov for NCT04776148
Serious adverse events (Up to approximately 41 months (through End of Trial database cut-off date of 27-Sep-2024)): Lenvatinib + Pembrolizumab 117 of 279; Standard Of Care Treatment 66 of 277 Source: ClinicalTrials.gov results for NCT04776148 (opens in a new tab)· imported Posted results as ClinicalTrials.gov prints them: primary outcome analyses and serious adverse event totals only. Registry facts, not reviewed by HealthTrade and not investment advice; filing-derived results are listed separately. Publications listing NCT04776148 (1), newest first
Citations from PubMed, U.S. National Library of Medicine; abstracts are not stored. A publication lists this study’s NCT number and may be a review that cites many studies. | ||||||
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Posted results are shown as ClinicalTrials.gov prints them; results from company and journal sources are entered by editors and listed separately. Full result tables are on ClinicalTrials.gov.
Trial quality
About CT-VCALoading trial quality…
FDA actions
No FDA approvals on record for this drug.
FDA recalls load here.
FDA drug shortages load here.
Orange Book patents load here.
FAERS adverse event counts load here.
Papers and preprints load here.
Community discussion loads here.
EU status (EMA)
EMA's medicines data lists no human medicine with the same active substance as TAS-102.
Source: European Medicines Agency (EMA), medicines data download.
Related news
No recent headlines mention this drug.
Sources
- ClinicalTrials.gov NCT04776148 (opens in a new tab) Licence: public-domain. Official registry record this listing came from
- ClinicalTrials.gov NCT05064059 (opens in a new tab) Licence: public-domain. Official registry record this listing came from
- ClinicalTrials.gov NCT05600309 (opens in a new tab) Licence: public-domain. Official registry record this listing came from
Record updated .
Dates come from company and FDA disclosures and can change. Nothing on this page is investment advice.